NVO 250404 50.00C(NVO250404C50000) Stock Price Today

0.00
0.000.00%

15min DelayClose Apr 10 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

joe black8

Yesterday 06:59

15% tomorrow

$Novo-Nordisk A/S (NVO.US)$ no time to catch it

NurseTrader Mmoo

Yesterday 04:09

$Novo-Nordisk A/S (NVO.US)$ ok time to weakup guys..

CatMeow

Yesterday 01:24

where is this going from here?

$Novo-Nordisk A/S (NVO.US)$
Is this stock seen as a long term (2 years) stock? I've already DCA down several times and my average is still at 85. When will I get out of this

Budwi Rifai : $Novo-Nordisk A/S (NVO.US)$ WILL BE $85 BEFORE U KNOW IT

Report
Reply

Cancel Reply
pootpoot : well trump said hes going to have heavy tariffs on pharmaceuticals.. email him to lift the tariffs.

Report
Reply

Cancel Reply
CatMeow OP pootpoot : you got his email?

Report
Reply

Cancel Reply
Money Thrill : Denmark has not yet imposed any import duties on America which is good news so everything will be fine. Novo also has a special new medicine >> through the acquisition of Cardiac Pharmaceuticals for 1 billion euros it has a good medicine for heart disease. Maybe a new blockbuster

Report
Reply

Cancel Reply
Money Thrill : Especially for you CatMeow ... don't worry ... wait shall go up to 100 and even more ...Novo Nordisk’s €1 billion investment in Cardior Pharmaceuticals strongly suggests potential blockbuster territory. Especially since it involves CDR132L, a novel RNA-based therapy for heart failure, a condition that affects millions of people worldwide.
Here are a few reasons why this could indeed be a potential blockbuster:
Novel mechanism of action: CDR132L targets microRNA-132, which plays a role in pathological cardiac tissue repair. By inhibiting this, the heart may be able to recover better after damage, something that existing drugs RARELY ADDRESS !!! THAT'S GOOD
Huge market potential: Heart failure is a leading cause of death worldwide, with more than 6 million patients in the US alone. There is an urgent need for novel therapies with truly impactful effects.
Competitive advantage: There are currently few effective, disease-modifying therapies on the market for heart failure, especially at the genetic or RNA level. If CDR132L lives up to its promise, it could be a first-in-class blockbuster.
Phase 2 clinical trials are already underway – an indication that Novo Nordisk is also buying time and getting closer to commercial launch with the acquisition.
So yes, there is a good chance that CDR132L will be their next big asset outside of the diabetes/obesity segment.
Conclusion... wait

Report
Reply

Cancel Reply